Novo Nordisk A/S

The US Federal Trade Commission sued CVS Health Corp., Cigna Group, and UnitedHealth Group Inc., accusing their pharmacy benefit managers of illegal rebate programs that inflated insulin prices. The FTC alleges that Caremark, Express Scripts, and Optum Rx accepted drugmakers' money to keep lower-cost insulin off their approved lists, shifting more costs onto patients. The PBMs defend their practices, arguing they protect consumers from rising drug costs, while the FTC aims to lower list prices for insulin and other drugs.

The global Biotechnology Market is projected to reach USD 6.24 trillion by 2032, driven by R&D investments, healthcare demand, and advancements in pharmaceuticals, agriculture, and environmental management.

DelveInsight's 'Hemophilia B Pipeline Insight, 2024' report details the global Hemophilia B treatment market, including clinical trials, therapies, and company developments. Key companies and therapies in various stages of development are highlighted, along with market drivers and barriers.

Novo Nordisk executive Ulrich Otte anticipates Ozempic will likely face price negotiations with the US government, as part of Biden's Inflation Reduction Act, with CMS set to announce selected drugs for negotiation by February 1, 2025.

Personalized medicine market to reach $900.67 Bn by 2030, driven by cancer therapies and genetic tech. North America leads, emphasizing personalized nutrition and expanding therapeutic applications.

Novo Nordisk A/S (NVO) reported Q2 2024 net sales of DKK133.41 billion, up 23.9% YoY, and raised full-year guidance. Analysts project 31.1% YoY growth in Q3 revenue to $10.96 billion, with EPS expected to climb 22.3% to $0.87. NVO's sales in Diabetes and Obesity care increased 26% to DKK125 billion, driven by GLP-1 sales and Obesity care growth. The company completed phase 3 FRONTIER 2 trial with Mim8 and received a positive CHMP opinion for Wegovy® label update. NVO raised its 2024 sales growth outlook to 22-28% and operating profit growth to 20-28%. Shares surged 30.1% over the past year.

Roche Holding AG remains unconcerned about side effects in a small study of its weight-loss shot CT-388, despite shares tumbling due to early release of side effect details. The company emphasizes no patients stopped treatment in the trial, and its other weight-loss candidate, CT-966, could be 'best in class.' Roche is focusing on five core therapy areas and diversifying in oncology, actively seeking partners in promising fields like antibody-drug conjugates.

Zealand Pharma plans to expand study of obesity drug dapiglutide, showing up to 8.3% weight loss in Phase 1b trial, aiming to release results for a 28-week study in H1 2025 and start a Phase 2b trial in H1 2024.

The oral thin films market is projected to reach $7.65 billion by 2028 with a CAGR of 13.6%, driven by specialty pharmaceuticals, precision medicine, and telemedicine. Key players include ZIM Laboratories, NAL Pharma, and Cure Pharmaceutical. The market is segmented by type, disease indication, and distribution channel.

News media often repeat drug makers' medical claims as news, giving pharma companies free advertising and potentially misleading consumers. Examples include a shingles vaccine's alleged dementia risk reduction, GLP-1 agonists' mental health benefits, and Xolair's new urticaria treatment, all linked to conflicts of interest. Medical journals complicate conflict of interest identification, and news media rarely investigate the sources of these claims.